ReviewHuman vaccines & immunotherapeutics2013
Nicotine vaccines to treat tobacco dependence.
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines' immunogenicity.Human vaccines & immunotherapeutics · 2022Pooled it
- Nicotine replacement therapy: insights into the mechanisms and potential of nicotine receptor pathway.American journal of translational research · 2025Review
- Article
- New medications development for smoking cessation.Addiction neuroscience · 2023Article
- A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice.NPJ vaccines · 2023Article
- COVID-19 Vaccine Hesitancy among Behavioral Risk Takers.Vaccines · 2022Article
- A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects.ImmunoTargets and therapy · 2022Review
- Mutual assistance of nucleus accumbens cannabinoid receptor-1 and orexin receptor-2 in response to nicotine: a single-unit study.Research in pharmaceutical sciences · 2021Article
- Novel Vaccine That Blunts Fentanyl Effects and Sequesters Ultrapotent Fentanyl Analogues.Molecular pharmaceutics · 2020Article
- Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins.Nanomedicine : nanotechnology, biology, and medicine · 2018Article
- An enzymatic advance in nicotine cessation therapy.Chemical communications (Cambridge, England) · 2018Article
- Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.Biomaterials · 2017Article
- Article
- A New Strategy for Smoking Cessation: Characterization of a Bacterial Enzyme for the Degradation of Nicotine.Journal of the American Chemical Society · 2015Article
- Multivalent polymers for drug delivery and imaging: the challenges of conjugation.Biomacromolecules · 2014Review
- Neuroimmune basis of methamphetamine toxicity.International review of neurobiology · 2014Review
- Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.Pharmacology & therapeutics · 2013Review
- Dose-Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light-Dark Test in Mice.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tobacco smoking is globally far more widespread than use of any other substance of abuse. Nicotine is an important tobacco constituent that is responsible for addictive properties of smoking. The currently available medications for the treatment of nicotine addiction have limited efficacy. A challenging novel therapeutic concept is vaccination against nicotine. An efficient vaccine would generate antibodies that sequester nicotine in the blood and prevent its access to the brain. The vaccine would have great potential for treating nicotine addiction and for relapse prevention. We reviewed the current status of vaccines against nicotine addiction that are undergoing clinical trials or are in preclinical development. We discuss problems associated with the development of nicotine vaccines, their efficacy in addiction treatment, challenges and ethical concerns. Existing evidence indicates that nicotine vaccination is well tolerated and capable of inducing an immune response but its effectiveness in increasing smoking abstinence has not been shown so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.